OTCPK:TLTF.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Canada, the United States, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Theralase Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TLTF.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.5%

TLTF.F

-2.5%

US Medical Equipment

-3.1%

US Market


1 Year Return

-26.0%

TLTF.F

14.6%

US Medical Equipment

12.7%

US Market

Return vs Industry: TLTF.F underperformed the US Medical Equipment industry which returned 14.6% over the past year.

Return vs Market: TLTF.F underperformed the US Market which returned 12.7% over the past year.


Shareholder returns

TLTF.FIndustryMarket
7 Day-8.5%-2.5%-3.1%
30 Day-21.2%-0.06%-2.9%
90 Day-27.7%13.9%8.2%
1 Year-26.0%-26.0%15.6%14.6%15.3%12.7%
3 Year-66.9%-66.9%71.4%67.0%37.8%28.5%
5 Year-44.6%-44.6%149.1%130.4%90.9%69.4%

Price Volatility Vs. Market

How volatile is Theralase Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Theralase Technologies undervalued compared to its fair value and its price relative to the market?

3.13x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TLTF.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TLTF.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TLTF.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: TLTF.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TLTF.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLTF.F is good value based on its PB Ratio (3.1x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Theralase Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

5.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLTF.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TLTF.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TLTF.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TLTF.F's revenue (83.2% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: TLTF.F's revenue (83.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TLTF.F is forecast to be unprofitable in 3 years.


Next Steps

  • Explore growth companies in the Healthcare industry.

Past Performance

How has Theralase Technologies performed over the past 5 years?

-5.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TLTF.F is currently unprofitable.

Growing Profit Margin: TLTF.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TLTF.F is unprofitable, and losses have increased over the past 5 years at a rate of 5.1% per year.

Accelerating Growth: Unable to compare TLTF.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLTF.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: TLTF.F has a negative Return on Equity (-72.71%), as it is currently unprofitable.


Next Steps

Financial Health

How is Theralase Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: TLTF.F's short term assets (CA$10.8M) exceed its short term liabilities (CA$802.4K).

Long Term Liabilities: TLTF.F's short term assets (CA$10.8M) exceed its long term liabilities (CA$64.6K).


Debt to Equity History and Analysis

Debt Level: TLTF.F is debt free.

Reducing Debt: TLTF.F had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLTF.F has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TLTF.F has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 4% each year.


Next Steps

Dividend

What is Theralase Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TLTF.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TLTF.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TLTF.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLTF.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLTF.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.8yrs

Average management tenure


CEO

Shawn Shirazi

0.92

Tenure

CA$347,148

Compensation

Dr. Shawn Shirazi Ph.D., is Chief Executive Officer at Theralase Technologies Inc. since October 31, 2019 and served as its Chief Executive Officer of Drug since February 25, 2019 until October 31, 2019. D ...


CEO Compensation Analysis

Compensation vs Market: Shawn's total compensation ($USD260.86K) is below average for companies of similar size in the US market ($USD601.89K).

Compensation vs Earnings: Insufficient data to compare Shawn's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Shawn Shirazi
Chief Executive Officer0.92yrCA$347.15kno data
Kristina Hachey
CFO & Director1.17yrsCA$533.82k0.79%
CA$ 206.5k
Arkady Mandel
Chief Scientific Officer & Director2.25yrsCA$638.82kno data
David Groves
President of World Trade Division13.83yrsno datano data
Roger Dumoulin-White
Director of Business Developmentno dataCA$300.80k3.71%
CA$ 967.4k
James Andrews
Chairman of Medical & Scientific Advisory Board and Medical Directorno datano datano data
Lori Leach
Marketing & Media Relations Consultant10.75yrsno datano data
Vaughn Wyant
Marketing & Media Relations Consultant10.75yrsno datano data
Terry Ruch
Equine Medical Consultant10.08yrsno datano data

10.8yrs

Average Tenure

Experienced Management: TLTF.F's management team is seasoned and experienced (10.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kristina Hachey
CFO & Director1.17yrsCA$533.82k0.79%
CA$ 206.5k
Arkady Mandel
Chief Scientific Officer & Director2.25yrsCA$638.82kno data
James Andrews
Chairman of Medical & Scientific Advisory Board and Medical Directorno datano datano data
Brian Wilson
Member of Medical & Scientific Advisory Board5.75yrsno datano data
Randy Bruder
Independent Director12.67yrsCA$238.82k0.87%
CA$ 228.0k
Michael Jewett
Member of Medical & Scientific Advisory Board7.67yrsno datano data
Matthew Perraton
Independent Director7.58yrsCA$238.82kno data
Guy Anderson
Independent Chairman of the Boardno dataCA$238.82k0.091%
CA$ 23.8k
Lothar Lilge
Member of Medical & Scientific Advisory Boardno datano datano data
Ashish Kamat
Member of Medical & Scientific Advisory Board5.75yrsno datano data
Michael O'Donnell
Member of Medical & Scientific Advisory Board5.75yrsno datano data

5.8yrs

Average Tenure

Experienced Board: TLTF.F's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TLTF.F insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Theralase Technologies Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Theralase Technologies Inc.
  • Ticker: TLTF.F
  • Exchange: OTCPK
  • Founded: 1995
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$34.727m
  • Listing Market Cap: CA$26.095m
  • Shares outstanding: 204.28m
  • Website: https://www.theralase.com

Number of Employees


Location

  • Theralase Technologies Inc.
  • 41 Hollinger Road
  • Toronto
  • Ontario
  • M4B 3G4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TLTTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 1996
TLTF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 1996
TTXDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 1996

Biography

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Can ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 06:58
End of Day Share Price2020/09/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.